Insider Buying: Kenneth Hoberman Acquires 2,000 Shares of Stemline Therapeutics Stock (STML)
Stemline Therapeutics (NASDAQ:STML) COO Kenneth Hoberman acquired 2,000 shares of Stemline Therapeutics stock on the open market in a transaction dated Tuesday, September 2nd. The shares were purchased at an average price of $10.99 per share, for a total transaction of $21,980.00. Following the completion of the purchase, the chief operating officer now directly owns 89,535 shares in the company, valued at approximately $983,990. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.
Stemline Therapeutics (NASDAQ:STML) traded up 0.09% during mid-day trading on Thursday, hitting $10.9299. 19,933 shares of the company’s stock traded hands. Stemline Therapeutics has a 52 week low of $10.509 and a 52 week high of $47.25. The stock has a 50-day moving average of $11.61 and a 200-day moving average of $16.36. The company’s market cap is $141.5 million.
Stemline Therapeutics (NASDAQ:STML) last released its earnings data on Thursday, August 14th. The company reported ($0.47) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.71) by $0.24. On average, analysts predict that Stemline Therapeutics will post $-2.39 earnings per share for the current fiscal year.
Stemline Therapeutics, Inc (NASDAQ:STML) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk.
Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.